title: Correlation of plasma brain-derived neurotrophic factor and metabolic profiles in drug-naïve patients with bipolar II disorder after a twelve-week pharmacological intervention.
abstract: OBJECTIVE
  Brain-derived neurotrophic factor (BDNF) is thought to be involved in the pathophysiology of bipolar disorder (BD) and metabolic syndrome. We investigated the correlation between plasma BDNF with mood symptoms and metabolic indices in patients with BD-II over a 12-week pharmacological intervention.
  
  
  METHODS
  Drug-naïve patients with BD-II (n=117) were recruited. Metabolic profiles [cholesterol, triglyceride, HbA1C, fasting serum glucose, body mass index (BMI)] and plasma BDNF wtrun "tblautotrun "tblsctrun "tbl_contere measured at baseline and 2, 8, and 12 weeks after beginning medication. To adjust within-subject dependence over repeated assessments, multiple linear regressions with generalized estimating equation methods were used.
  
  
  RESULTS
  Seventy-six (65.0%) patients completed the intervention. Plasma BDNF levels were significantly associated with BMI (P=9.6E-5), low-density lipoprotein (P=0.034) and total (P=0.001) cholesterol, but not with the Hamilton Depression Rating Scale-17 and Young Mania Rating Scale scores over the 12-week treatment.
  
  
  CONCLUSIONS
  We found initial evidence of a positive correlation between plasma BDNF levels and BMI, low-density lipoprotein and total cholesterol in drug-naïve patients with BD-II. The specific function of BDNF in regulating and maintaining peripheral metabolic health requires additional investigation.
authors.affiliation: Department of Psychiatry, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan; Department of Psychiatry, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
authors.forename: S-Y
authors.initials: SY
authors.lastname: Lee
authors.forename: S-L
authors.initials: SL
authors.lastname: Chen
authors.forename: Y-H
authors.initials: YH
authors.lastname: Chang
authors.forename: P-S
authors.initials: PS
authors.lastname: Chen
authors.forename: S-Y
authors.initials: SY
authors.lastname: Huang
authors.forename: N-S
authors.initials: NS
authors.lastname: Tzeng
authors.forename: C-L
authors.initials: CL
authors.lastname: Wang
authors.forename: L-J
authors.initials: LJ
authors.lastname: Wang
authors.forename: I-H
authors.initials: IH
authors.lastname: Lee
authors.forename: T-Y
authors.initials: TY
authors.lastname: Wang
authors.forename: K-C
authors.initials: KC
authors.lastname: Chen
authors.forename: Y-K
authors.initials: YK
authors.lastname: Yang
authors.forename: J-S
authors.initials: JS
authors.lastname: Hong
authors.forename: R-B
authors.initials: RB
authors.lastname: Lu
mesh_terms: D000328:Adult; D000339:Affect / Q000187:drug effects; D001714:Bipolar Disorder / Q000097:blood* / Q000188:drug therapy* / Q000523:psychology; D015992:Body Mass Index; D019208:Brain-Derived Neurotrophic Factor / Q000097:blood*; D002784:Cholesterol / Q000097:blood; D005260:Female; D005473:Fluoxetine / Q000627:therapeutic use; D006801:Humans; D016014:Linear Models; D008077:Lipoproteins, LDL / Q000097:blood; D008137:Longitudinal Studies; D008140:Lorazepam / Q000627:therapeutic use; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood / Q000378:metabolism; D011569:Psychiatric Status Rating Scales; D016896:Treatment Outcome; D014635:Valproic Acid / Q000627:therapeutic use
chemical_list: D019208:Brain-Derived Neurotrophic Factor; D008077:Lipoproteins, LDL; D005473:Fluoxetine; D014635:Valproic Acid; C579455:BDNF protein, human; D002784:Cholesterol; D008140:Lorazepam
keywords: bipolar II disorder; body mass index; brain-derived neurotrophic factor; metabolic syndrome